Search research articles
Contact Us
Filters
Showing results (161-170 of 196) with videos related to
Page
of 20
Sort By:
Minerva Urology and Nephrology
|
June 26, 2024
The impact of venous thromboembolism before open or minimally-invasive radical cystectomy in the USA: insurance claims data on perioperative outcomes and healthcare costs
Francesco Del Giudice, Anas Tresh, Shufeng Li, et al.
BJU International
|
March 12, 2024
The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer
Markus von Deimling, Laura S Mertens, Marc Furrer, et al.
BJU International
|
March 13, 2026
Risk stratification and conditional recurrence after radical cystectomy: toward adaptive follow-up
Roberto Contieri, Alberto Martini, Marc Furrer, et al.
BJU International
|
December 20, 2021
Nomograms including the UBC<sup>®</sup> Rapid test to detect primary bladder cancer based on a multicentre dataset
Christina J Meisl, Pierre I Karakiewicz, Roland Einarsson, et al.
Cancer Immunology, Immunotherapy : CII
|
March 24, 2026
Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)
Veronica Mollica, Francesco Massari, Kazutoshi Fujita, et al.
Minerva Urology and Nephrology
|
April 23, 2026
Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study)
Marco Maruzzo, Alexandr Poprach, Sebastiano Buti, et al.
Therapeutic Advances in Medical Oncology
|
April 7, 2022
Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study
Klaus-Peter Dieckmann, Tomas Pokrivcak, Lajos Geczi, et al.
Cancer Immunology, Immunotherapy : CII
|
November 14, 2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study
Ray Manneh Kopp, Francesco Massari, Enrique Grande, et al.
European Urology Open Science
|
June 17, 2025
Prevalence and Prognostic Significance of Preoperative Anemia in Radical Cystectomy Patients: A Multicenter Retrospective Observational Study
Ernest Kaufmann, Luca Antonelli, Luca Afferi, et al.
BJU International
|
July 4, 2024
Thromboprophylaxis during neoadjuvant chemotherapy for bladder cancer reduces thromboembolism and bleeding
Luca Antonelli, Pedro David Wendel-Garcia, Manja Deforth, et al.
Page
of 20
Search research articles
Search
Showing results (161-170 of 196) with videos related to
Sort By:
Page
of 20
Minerva Urology and Nephrology
|
June 26, 2024
The impact of venous thromboembolism before open or minimally-invasive radical cystectomy in the USA: insurance claims data on perioperative outcomes and healthcare costs
Francesco Del Giudice, Anas Tresh, Shufeng Li, et al.
BJU International
|
March 12, 2024
The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer
Markus von Deimling, Laura S Mertens, Marc Furrer, et al.
BJU International
|
March 13, 2026
Risk stratification and conditional recurrence after radical cystectomy: toward adaptive follow-up
Roberto Contieri, Alberto Martini, Marc Furrer, et al.
BJU International
|
December 20, 2021
Nomograms including the UBC<sup>®</sup> Rapid test to detect primary bladder cancer based on a multicentre dataset
Christina J Meisl, Pierre I Karakiewicz, Roland Einarsson, et al.
Cancer Immunology, Immunotherapy : CII
|
March 24, 2026
Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)
Veronica Mollica, Francesco Massari, Kazutoshi Fujita, et al.
Minerva Urology and Nephrology
|
April 23, 2026
Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study)
Marco Maruzzo, Alexandr Poprach, Sebastiano Buti, et al.
Therapeutic Advances in Medical Oncology
|
April 7, 2022
Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study
Klaus-Peter Dieckmann, Tomas Pokrivcak, Lajos Geczi, et al.
Cancer Immunology, Immunotherapy : CII
|
November 14, 2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study
Ray Manneh Kopp, Francesco Massari, Enrique Grande, et al.
European Urology Open Science
|
June 17, 2025
Prevalence and Prognostic Significance of Preoperative Anemia in Radical Cystectomy Patients: A Multicenter Retrospective Observational Study
Ernest Kaufmann, Luca Antonelli, Luca Afferi, et al.
BJU International
|
July 4, 2024
Thromboprophylaxis during neoadjuvant chemotherapy for bladder cancer reduces thromboembolism and bleeding
Luca Antonelli, Pedro David Wendel-Garcia, Manja Deforth, et al.
Page
of 20